DFW Weight Loss Guide
GLP-1 Basics · 2026

GLP-1 medications, explained in plain English.

What they do, what they cost, and what's changed in 2026 — new pills, new prices, new rules. The plain-English version of where things actually stand.

Last updated: [DATE]
Physician-reviewed
How they work

Three things at once

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after you eat. These medications mimic it.

Quiets appetite

Tells your brain you're full — food noise fades.

Slows stomach emptying

You stay satisfied longer between meals.

Improves insulin response

Helps your body release insulin when blood sugar rises.

Not willpower in a syringe — the biological signals pushing you to eat get turned down far enough that eating less stops feeling like a fight.

The medications, by name

Semaglutide, tirzepatide, and what's next

Semaglutide

Wegovy · Ozempic · Wegovy pill (2026)

~15% avg body-weight loss

Weekly injection, plus the first oral GLP-1 for weight loss approved January 2026 — trial average ~17% for those who stayed on the pill.

Tirzepatide

Zepbound · Mounjaro

up to ~20% avg body-weight loss

Dual-hormone (GLP-1 + GIP). In head-to-head research, produced somewhat greater average weight loss than semaglutide. Injection-only for now.

Orforglipron (coming)

Eli Lilly — FDA review

Second oral GLP-1 expected

Moving through FDA review — a second pill option is expected to reach the market soon.

If a provider offers you something noton this list — a "GLP-1 blend," a peptide with a research-chemical name, or a vial with no brand — that's a sourcing question you should ask out loud.

What changed

2025–2026 timeline

Why your options look different than a year ago.

Late 2024

FDA-declared tirzepatide shortage ended.

Early 2025

Semaglutide shortage ended — mass-compounding pathway closes.

January 2026

Wegovy oral pill launched — first oral GLP-1 for weight loss.

April 2026

FDA moved to permanently exclude these drugs from large-scale compounding.

July 2026

Medicare demonstration program covers Zepbound at $50 copay for qualifying beneficiaries.

A narrow, patient-specific compounding pathway still exists through traditional pharmacies — but if you're being offered compounded GLP-1s at scale in mid-2026, ask hard questions about exactly what's in the vial.

Side effects

Common, and call-your-doctor

Common & manageable

·Nausea (especially early and after dose increases)
·Constipation or diarrhea
·Fatigue
·Reflux

These typically ease as your body adjusts. A provider who titrates dose to your response can minimize them.

Call a clinician

·Vomiting you can't keep ahead of
·Signs of dehydration
·Severe abdominal pain (rare pancreatitis)
·Gallbladder symptoms
·Vision changes (if you have diabetes)

The practical argument for an accessible prescriber who's actually managing you.

Continued reading

Who shouldn't take them

GLP-1s aren't for everyone. They're generally not appropriate if you have a personal or family history of medullary thyroid carcinoma or MEN 2 (the medications carry a boxed warning on this), a history of pancreatitis, or if you're pregnant, trying to become pregnant, or breastfeeding. People with a history of eating disorders, significant gastrointestinal disease, or on certain interacting medications need individualized evaluation, not a questionnaire. This is exactly the screening a real intake process exists to do.

Realistic expectations

Trial averages: roughly 15% body-weight loss with semaglutide, around 17% with the Wegovy pill among those who stayed on it, and up to ~20% with tirzepatide — over a year or more, not weeks. Averages hide wide variation: some people lose more, a meaningful minority respond only modestly.

Two things nobody's ads mention:

Everyone plateaus.Usually somewhere in months 6–12. What happens next depends on whether your program has more tools than "increase the dose."
Not all lost weight is fat.A meaningful share of rapid weight loss can be lean muscle unless you're deliberately protecting it with adequate protein and resistance training.

Getting started safely

Whichever care model you choose — and the differences between them are bigger than most people realize — the safe starting sequence is the same: a real medical history, baseline lab work, an honest conversation about your goals and the exit plan, then a starting dose with scheduled follow-up. Physician-led practices such as build that screening into intake as standard; if the provider you're considering doesn't, our will surface it fast.

Frequently Asked Questions

What's the difference between Ozempic and Wegovy?

Same active ingredient (semaglutide), different FDA approvals and dosing: Ozempic is approved for type 2 diabetes, Wegovy for weight management and cardiovascular risk reduction. Insurance treats them very differently, which is usually what actually matters.

Is there a GLP-1 pill, or only injections?

As of 2026, yes — the Wegovy pill (daily oral semaglutide) launched in January and delivered weight loss comparable to the weekly injection in trials. It requires taking it on an empty stomach with a waiting period before eating. A second pill from Eli Lilly is expected.

Is compounded semaglutide still legal in 2026?

Mostly no, at scale. The shortage-era pathway that allowed mass compounding is gone and the FDA has moved to close the remaining bulk-production route permanently. A narrow patient-specific pathway exists. Treat any low-cost compounded offer as something to investigate, not a bargain to grab.

Do you gain the weight back when you stop?

Without a maintenance plan, studies show most people regain a substantial portion — the biology the medication was quieting comes back. With a deliberate plan (nutrition, strength training, sometimes a lower maintenance dose or a taper), the picture is much better. Ask any provider what stopping looks like before you start.

How long do you have to take a GLP-1?

These are designed as long-term medications for a chronic condition, but “long-term” doesn't have to mean “forever at full dose.” The honest answer varies by person — which is an argument for a prescriber who knows you rather than a subscription that renews.

Medically reviewed by [REVIEWER NAME, MD] — [DATE].